| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Acquired patents, net | NaN | NaN | NaN | 0 |
| Cash | 10,505,435 | 6,178,021 | 3,806,978 | 3,125,101 |
| Total current assets | 10,505,435 | 6,178,021 | NaN | NaN |
| Total assets | 10,505,435 | 6,178,021 | 3,806,978 | 3,125,101 |
| Unreimbursed expenses related party-Related Party | NaN | NaN | NaN | 82,852 |
| Deferred compensation related party-Related Party | NaN | NaN | NaN | 306,281 |
| Accounts payable & accrued interest | 4,509,028 | 4,874,489 | 1,108,886 | 1,296,476 |
| Deferred compensation related party | NaN | NaN | 306,281 | NaN |
| Deferred compensation | 673,819 | 673,819 | NaN | NaN |
| Unreimbursed expenses | 52,382 | 276,496 | 206,834 | NaN |
| Total current liabilities | 5,235,229 | 5,824,804 | 1,622,001 | 1,685,609 |
| Total liabilities | 5,235,229 | 5,824,804 | 1,622,001 | 1,685,609 |
| Common stock, 0.001 par value 100,000,000 shares authorized 14,665,993 and 14,298,446 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively | 14,666 | 14,299 | 13,795 | 13,473 |
| Additional paid-in capital | 98,049,683 | 87,475,924 | 79,760,045 | 74,863,037 |
| Accumulated deficit | -92,794,143 | -87,137,006 | -77,588,863 | -73,437,018 |
| Total stockholders equity | 5,270,206 | 353,217 | 2,184,977 | 1,439,492 |
| Total liabilities and stockholders equity | 10,505,435 | 6,178,021 | 3,806,978 | 3,125,101 |
Greenwich LifeSciences, Inc. (GLSI)
Greenwich LifeSciences, Inc. (GLSI)